Oslo, 8 March 2021 – Targovax ASA, today announces that members of its executive management team is invited to present and participate at upcoming conferences.
H.C. Wainwright Annual Global Life Sciences Conference, virtual
Date: 9 March 2021
Presenter: Øystein Soug (CEO)
Time: 13:00 CET
Carnegie Healthcare Seminar, virtual
Date: 12 March 2021
Presenter: Øystein Soug (CEO)
Time: 12:45 CET
Roth Capital 33rd Annual Conference, virtual
Date: 15-17 March 2021
1×1 meetings
Tumor Myeloid Microenvironment Directed Therapeutics, virtual
Date: 17 March
Presenter: Victor Levitsky (CSO)
Time: 22:45 CET
European Biotech Investor Days 2021, virtual
Date: 7-8 April 2021
Presenter: Øystein Soug (CEO)
Time: To be scheduled
***
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz – LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients with targeted therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging data in several indications, in monotherapy and in multiple combination, the next development steps for ONCOS-102 will involve a clinical trial with registration intent in checkpoint inhibitor refractory melanoma.